Complement Function/Activity Test
Complement function or activity test allows for the determination of whether the protein is present and whether it has normal functional activity. A wide range of assays are now available in Creative Biolabs, such as Hemolysis assays (CH50 or AH50), Elisa Assays (c3a, c5a, FH, FB, C5b-9 or others), Complement Inhibitor Validation (IC50)......
Creative Biolabs’ technical experts have successfully established the proprietary complement therapeutics system. We are looking forward to designing a strategy to carry on the therapeutic antibodies development services for our clients in complement therapeutic.
Complement Related Disease
The complement system is a central component of innate immunity and bridges the innate to the adaptive immune response. However, it can also turn its destructive capabilities against host cells and is involved in numerous diseases and pathological conditions. An imbalance in complement, either by insufficient or excessive complement activity, can have important pathological consequences. Antibody-based treatments can be employed to restore the balance in the complement network in order to achieve therapeutic effects. Complement inhibition can be beneficial in pathologies where the system is hyperactivated or where it is chronically activated and attacks or damages healthy tissues.
Following a general trend in the pharmaceutical industry, antibody-based therapeutics appears to be the most rapidly growing drug class against complement-related diseases. Crucial developments have done in their screening, production and humanization antibodies. By targeting specific components of the complement system, all stages from the initiation and activation process to single terminal actions can hypothetically be blocked in a selective manner.
Based on the advanced technology and rich experience, Creative Biolabs offers a comprehensive service of therapeutic antibodies development for our clients. Until now, our services including but not limited to:
As a key component of the complement system, C5 has been thoroughly studied in recent years. We provide antibody development services against the C5 target to meet your requirements. Here are two examples:
We also provide antibody development services against the CD20 target. For example, an antibody has been developed as a human mAb that targets an epitope encompassing the membrane-proximal small-loop on the CD20 molecule, which differs from the binding location of rituximab. In vitro studies of this antibody have demonstrated that it is significantly more effective than rituximab at corresponding dose levels at lysing CLL cells and B-cell lines, especially those with low CD20 copy numbers.
Fig.1 Complement-dependent Cytotoxicity (CDC) and Antibody-dependent Cellular Cytotoxicity (ADCC) of Tumor Cells.
CD46, also known as membrane cofactor protein (MCP), acts as an inhibitory complement receptor to play the critical role in self-protection from the destructive action of autologous complement. Now, it has become an important target for therapeutic antibody exploration.
CD55, also known as decay-accelerating factor (DAF), is a glycosylphosphatidylinositol (GPI)-anchored membrane protein that inhibits both the classical and the alternative pathways of complement activation. It functions as a membrane-bound complement inhibitor to protect host cells from the destructive action of autologous complement.
CD59 is also known as MAC-inhibitory protein (MAC-IP), membrane inhibitor of reactive lysis (MIRL), or protectin. It acts as an inhibitory complement receptor to protect host cells from self-destruction by complement-mediated lysis. Now, it has become a potential target for therapeutic antibody exploration.
If you are interested in using our therapeutic antibodies service to support your antibody discovery and development program, please contact us by sending us your detailed request through e-mail. A formal quote will be sent back to you soon.